methylphenidate has been researched along with Death, Sudden, Cardiac in 15 studies
Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.
methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.
methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.
Death, Sudden, Cardiac: Unexpected rapid natural death due to cardiovascular collapse within one hour of initial symptoms. It is usually caused by the worsening of existing heart diseases. The sudden onset of symptoms, such as CHEST PAIN and CARDIAC ARRHYTHMIAS, particularly VENTRICULAR TACHYCARDIA, can lead to the loss of consciousness and cardiac arrest followed by biological death. (from Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 7th ed., 2005)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Methylphenidate is an important element of therapeutic strategies for ADHD." | 1.40 | [Cardiovascular risks and management during Attention Deficit Hyperactivity Disorder treatment with methylphenidate]. ( Acquaviva, E; Bange, F; Delorme, R; Le Heuzey, MF; Mouren, MC, 2014) |
| "Reports on sudden cardiac death (SCD) of children and adolescents treated with stimulant agents have raised concerns regarding the need for cardiovascular monitoring and risk stratification schedules." | 1.38 | Late potentials in the signal-averaged electrocardiogram in pre-pubertal children with ADHD, before and after methylphenidate treatment. ( Glazer, J; Golubchik, P; Imbar, S; Nahshoni, E; Sever, J; Shoval, G; Strasberg, B; Weizman, A; Zalsman, G, 2012) |
| " Dosage was inversely associated with risk." | 1.38 | Methylphenidate and risk of serious cardiovascular events in adults. ( Bilker, WB; Cziraky, MJ; Daniel, GW; Guevara, JP; Hennessy, S; Kimmel, SE; Newcomb, C; Schelleman, H; Strom, BL, 2012) |
| " Despite their efficacy and long history of use, there is concern about their potential for adverse cardiovascular effects in children and adolescents." | 1.36 | Cardiovascular safety of stimulant medications for pediatric attention-deficit hyperactivity disorder. ( Muniz, R; Silva, RR; Skimming, JW, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bange, F | 1 |
| Le Heuzey, MF | 1 |
| Acquaviva, E | 1 |
| Delorme, R | 1 |
| Mouren, MC | 1 |
| Awudu, GA | 1 |
| Besag, FM | 1 |
| Banaschewski, T | 1 |
| Silva, RR | 1 |
| Skimming, JW | 1 |
| Muniz, R | 1 |
| Nahshoni, E | 1 |
| Golubchik, P | 1 |
| Glazer, J | 1 |
| Sever, J | 1 |
| Strasberg, B | 1 |
| Imbar, S | 1 |
| Shoval, G | 1 |
| Weizman, A | 1 |
| Zalsman, G | 1 |
| Batra, AS | 1 |
| Alexander, ME | 1 |
| Silka, MJ | 1 |
| Kratochvil, CJ | 1 |
| Schelleman, H | 1 |
| Bilker, WB | 1 |
| Kimmel, SE | 1 |
| Daniel, GW | 1 |
| Newcomb, C | 1 |
| Guevara, JP | 1 |
| Cziraky, MJ | 1 |
| Strom, BL | 1 |
| Hennessy, S | 1 |
| Langendijk, PN | 1 |
| Wilde, AA | 1 |
| Knight, M | 1 |
| Vitiello, B | 1 |
| Maloney, MJ | 1 |
| Schwam, JS | 1 |
3 reviews available for methylphenidate and Death, Sudden, Cardiac
| Article | Year |
|---|---|
Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder: an update.
Topics: Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Blood Pressu | 2014 |
Attention-deficit/hyperactivity disorder, stimulant therapy, and the patient with congenital heart disease: evidence and reason.
Topics: Amphetamines; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Coro | 2012 |
Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Appetite; Atomoxetine Hydrochloride; Attention Deficit Dis | 2008 |
12 other studies available for methylphenidate and Death, Sudden, Cardiac
| Article | Year |
|---|---|
[Cardiovascular risks and management during Attention Deficit Hyperactivity Disorder treatment with methylphenidate].
Topics: Attention Deficit Disorder with Hyperactivity; Blood Pressure; Central Nervous System Stimulants; Ch | 2014 |
[Joint position of the Guideline Group of the European Network for Hyperkintetic Disorders (EUNETHYDIS) and the German Central ADHD Network for ECG Recording on methylphenidate prescriptions].
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Death, Sudd | 2008 |
Cardiovascular safety of stimulant medications for pediatric attention-deficit hyperactivity disorder.
Topics: Adolescent; Adult; Amphetamines; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Card | 2010 |
Late potentials in the signal-averaged electrocardiogram in pre-pubertal children with ADHD, before and after methylphenidate treatment.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2012 |
ADHD pharmacotherapy: rates of stimulant use and cardiovascular risk.
Topics: Attention Deficit Disorder with Hyperactivity; Blood Pressure; Central Nervous System Stimulants; De | 2012 |
Methylphenidate and risk of serious cardiovascular events in adults.
Topics: Adult; Aged; Central Nervous System Stimulants; Cohort Studies; Databases, Factual; Death, Sudden, C | 2012 |
Encouraging news about ADHD drugs and heart risk in adults.
Topics: Adult; Attention; Attention Deficit Disorder with Hyperactivity; Cardiovascular Diseases; Central Ne | 2012 |
Second FDA panel advises on stimulants.
Topics: Advisory Committees; Central Nervous System Stimulants; Death, Sudden, Cardiac; Drug Labeling; Hallu | 2006 |
[Medication for ADHD and the risk of cardiovascular mortality].
Topics: Amphetamine; Arrhythmias, Cardiac; Attention Deficit Disorder with Hyperactivity; Cardiovascular Dis | 2006 |
ADHD update: new data on the risks of medication.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hype | 2006 |
Stimulant-drug therapy for attention-deficit disorder (with or without hyperactivity) and sudden cardiac death.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Death, Sudd | 2007 |
Clonidine and sudden death.
Topics: Child; Clonidine; Death, Sudden, Cardiac; Drug Therapy, Combination; Female; Humans; Male; Methylphe | 1995 |